Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 4, 2026
- Vaxcyte reported that VAX-31 met all prespecified primary endpoints in the OPUS-1 pivotal Phase 3 trial. Third-quarter net loss was $297.1 million, while cash, cash equivalents and investments totaled $2,264.4 million as of September 30, 2026.
- 10-Q report · filed Nov 4, 2026
- VAX-31 met all prespecified primary endpoints in the pivotal adult Phase 3 OPUS-1 trial and was well tolerated. Vaxcyte raised approximately $1.15 billion in October 2026 and held $2.3 billion of cash, cash equivalents and investments as of September 30, 2026.
The audio replay and transcript follow the call.